Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent New York Times Article "Drug Firms Face Billions in Losses in '11 as Patents End"

/ Source: GlobeNewswire

DURHAM, N.C., March 10, 2011 (GLOBE NEWSWIRE) -- Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp. (OTCQB:CURX) (Frankfurt: 8CX), commented today on an article by Duff Wilson published in the New York Times on March 6, 2011. According to Mr. Smith, the article titled " Drug Firms Face Billions in Losses in '11 as Patents End," which discusses the rationale for investing in Big Pharma while patents are expiring and drug pipelines are virtually empty, can be viewed as positive news for Curaxis.

"Mr. Wilson's article mentions the recent failures of Alzheimer's drugs in FDA trials sponsored by major pharmaceutical companies, which were largely based on beta amyloid that have shown no statistical significance in the trials, as well as having serious side effects on patients. Curaxis is taking a different approach to treating Alzheimer's with a form of leuprolide proven to be extremely safe by reducing the overproduction of a leutenizing hormone that is commonly found in older people and scientific research has shown to be a contributing factor to Alzheimer's," said Mr. Smith

Curaxis' lead hormone drug candidate Memryte has shown statistical results which appear equal to, if not better, than those reported of any Alzheimer's drug in FDA trials according to some specialists in the field. Memryte, which targets the primary pathological events of Alzheimer's disease, has also shown to stabilize Alzheimer's in patients who have a moderate to advanced phase of the disease.

Curaxis plans to enter Phase IIb trials to verify these findings and provide additional support that Memryte works to stabilize Alzheimer's in combination with certain drugs known as acetylcholinesterase inhibitors ("AChEIs"), of which Aricept is the most widely prescribed and going off patent this year. Curaxis has on file a patent pending for use of Memryte with AChEIs.

"Our clinical work has shown a synergistic effect with Aricept, and we believe the combination provides a better outcome when Memryte stops the aberrant cell cycling, allowing Aricept to work more effectively for a longer duration," added Mr. Smith. "We anticipate securing patents to provide a combination treatment at a very competitive price. Our findings are encouraging due to the safety of both drugs for many patient years."

About Curaxis

Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease and multiple cancers.  Curaxis' therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals.  This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers.

Notice Regarding Forward Looking Statements

This press release includes certain "Forward-Looking Statements" within the meaning of section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding potential results and future plans and objectives of Curaxis Pharmaceutical Corporation are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the Securities and Exchange Commission. Other risk factors may include, but are not limited to, fluctuation in quarterly results, and increased competition in our operations, our ability to continue operations as scheduled, and our ability to protect the proprietary technology we use. Further, the company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the company's control, such as announcements by competitors and service providers.

The contents of this press release are presented as a general overview of the company. It is intended only to contain general information regarding the company and its business and does not purport to provide complete disclosure or analysis of all matters, which may be relevant to a decision to make an investment, including all risk factors or similar considerations. Although the information is believed current as of the date herein, the information may be subject to change, amendment or supplementation, and the company does not expect, and assumes no obligation, to update or otherwise revise the information herein.

CONTACT: CURAXIS Pharmaceutical Corp. David Corcoran European Advisor: Andreea Porcelli 0035-2-2088-0289